A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer

A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancer - Biomarker study of T-DM1 for HER2-positive non-small cell lung cancer

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019446

Enrollment

Registered

2015-10-21

Start date

2015-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-positive, recurrent, non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Enrolled on a study of trastuzumab emtansine in patients with HER2-positive recurrent metastatic non-small cell lung cancer (HER2-CS-2 study) (2)Written informed consent

Exclusion criteria

Exclusion criteria: There are no special instruction regarding this section.

Design outcomes

Primary

Measure	Time frame
Identification of biomarkers related to efficacy of or resistance to T-DM1 for patients with HER2-positive non-small cell lung cancer	—

Countries

Japan

Contacts

Public ContactHiroe Kayatani

Okayama University Hospital Allergy and respiratory medicine

hk64hk85@yahoo.co.jp086-235-7227

Outcome results